Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule

被引:6
作者
Ando, Y [1 ]
Minami, H [1 ]
Saka, H [1 ]
Ando, M [1 ]
Sugiura, S [1 ]
Sakai, S [1 ]
Shimokata, K [1 ]
机构
[1] NAGOYA FIRST HOSP,JAPANESE RED CROSS,DEPT INTERNAL MED,NAKAMURA KU,NAGOYA,AICHI 453,JAPAN
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1997年 / 88卷 / 05期
关键词
carboplatin; pharmacokinetics; creatinine clearance; lung cancer;
D O I
10.1111/j.1349-7006.1997.tb00412.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated whether carboplatin pharmacokinetics is altered when the drug is delivered daily over 5 days, compared to a single-day infusion. Carboplatin was infused in 11 patients with lung cancer, who were randomly assigned to 2 groups. In the first group, the agent was administered on a conventional single-day schedule in the first course and then on a 5-day schedule in the second course. In the second group, the order was reversed (crossover design). The dose was calculated using Calvert's formula with 24 h creatinine clearance (Cer, ml/min) as a substitute for glomerular filtration rate (GFR): carboplatin (mg) = AUC x (Cer + 25), where AUC denotes the area under the concentration versus time curve (mg ml(-1) min). No difference of carboplatin clearance between the single-day and 5-day schedule was observed (94.8 +/- 19.9 versus 96.1 +/- 29.9 ml/min, P = 0.818, paired t test). The formula systematically overestimated the carboplatin clearance; the ratio of estimated clearance/observed clearance ranged from 1.01 to 1.58 (median 1.28; 95% confidence interval, 1.18 to 1.39). We concluded that the individual dosing strategy based on renal function can be applied with a 5-day schedule as well as a single-day schedule. Carboplatin is overdosed when Cer is substituted for GFR in Calvert's formula.
引用
收藏
页码:517 / 521
页数:5
相关论文
共 19 条
[1]  
ARMITAGE P, 1994, STAT METHODS MED RES, P195
[2]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[3]   A PHARMACOLOGICALLY GUIDED PHASE-I STUDY OF CARBOPLATIN COMBINATION WITH METHOTREXATE AND VINBLASTINE IN ADVANCED UROTHELIAL CANCER [J].
CHATELUT, E ;
CHEVREAU, C ;
BRUNNER, V ;
MARTINEZ, M ;
HOUIN, G ;
BUGAT, R ;
CANAL, P .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (05) :391-396
[4]  
DAUGAARD G, 1988, CANCER CHEMOTH PHARM, V21, P163
[5]  
EGORIN MJ, 1984, CANCER RES, V44, P5432
[6]  
HARLAND SJ, 1984, CANCER RES, V44, P1693
[7]   2-PERIOD CROSSOVER CLINICAL-TRIAL [J].
HILLS, M ;
ARMITAGE, P .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 8 (01) :7-20
[8]  
KYRIAZIS AP, 1985, CANCER RES, V45, P4354
[9]  
KYRIAZIS AP, 1985, CANCER RES, V45, P2012
[10]   ESTIMATION OF VARIANCE FOR HARMONIC MEAN HALF-LIVES [J].
LAM, FC ;
HUNG, CT ;
PERRIER, DG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1985, 74 (02) :229-231